The team of experts
Verlyx Pharma Inc. is a privately-held pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. Verlyx’s lead product, VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. Verlyx has initiated a purposeful clinical program based on VLX103, aiming at three important unmet needs in the field of liver diseases: NASH and ASH.
Verlyx Pharma relies on accomplished individuals whose complementary expertise brings a high level of knowledge, innovation and management to the company. This team coordinates a network of collaborators and investigators dedicated to the success of the company and its products.
Pierre Falardeau, PhD
President and Chief Executive Officer
Pierre Falardeau joined Verlyx Pharma in January 2010, as President and Chief Executive Officer. Dr. Falardeau has broad experience in drug development acquired over several years in the field of oncology. He is the founder of Consultation Pharm-Asset Inc., a consultation services in decision-support committed to delivering evidence-based business guidance to support global success in the pharmaceutical and biopharmaceutical industry, including financing strategy, portfolio optimization and product development.
From 2002 to 2007, Dr. Falardeau was President and Chief Executive Officer of Ecopia Biosciences Inc., until the merger of Ecopia with Caprion Pharmaceutical to form Thallion Pharmaceuticals, of which Dr. Falardeau became the Chief Operating Officer until 2009. From 1998 to 2002, he held increasingly responsible positions at Æterna-Zentaris, first as Director, Scientific Affairs, then as Vice-President, Scientific Affairs, with a focus in oncology.
From 1987 to 1991, Dr. Falardeau did his post-doctoral training at the Howard Hughes Medical Institute at Duke University, in Durham, North Carolina. Dr. Falardeau obtained his PhD in pharmacology and physiology in 1987 at Laval University, in Quebec City.
Patrick Colin, BPharm, PhD
Senior Vice-President and Chief Development Officer
Dr. Colin is Senior Vice-President and Chief Development Officer of Verlyx Pharma. He was formerly Vice-President, Clinical Development of the company, leading the clinical development and pharmacovigilance activities of Verlyx since he joined the company in 2011.
Dr. Colin has spent more than 12 years at Axcan Pharma (today Aptalis Pharma), where he established and led the drug development department as the Vice-President, R&D. His credentials include 25 years of global drug development experience, and more than 15 market approvals in the US, EU, Canada and Australia. Patrick Colin graduated from the Faculty of Pharmacy at the University of Montreal, where he obtained both a professional Pharmacy degree (BPharm) as well as a PhD in pharmacology.
Director of Operations
Marie-Noëlle Ip joined the Verlyx team in May, 2009. From 1989 to 2003, she worked at BCE Inc., initially in the legal department, then in corporate strategy. She subsequently worked in the Office of the Prime Minister of Canada as Executive Assistant and Researcher in the policy group. Prior to joining Verlyx, she was a Program Director at the Ottawa-based Council of Canadian Academies, managing the conduct of assessments by expert panels on the science underlying pressing issues and matters of public interest.
Micheline Beauvais, CPA, CGA, MBA
From the banking industry to CFO of Locus Dialogue Inc. she has been working as part-time CFO since 2002 for small Venture-Backed technology start-up companies, ranging from biotechs to internet ventures. As Certified General Accountant, she successfully completed her Executive MBA at Concordia University in Montreal.
Jianmin Duan, PhD
Advisor, DMPK & Biostatistics
Dr. Jianmin Duan obtained his PhD in Pharmacology in 1989 from Dalhousie University in Halifax. Following a post-doc training in Pharmacology and Toxicology at the University of Western Ontario, Jianmin worked for 21 years in drug discovery and development at Boehringer Ingelheim Canada Ltd. His pharmacology and pharmacokinetic expertise, as well as strategic leadership roles in drug R&D was well recognized and rewarded with four promotions, leading to the position of preclinical PK/PD Director.
Jianmin founded his own pharmaceutical consulting company in 2013. His responsibility at Verlyx is to effectively apply translational PK/PD approaches to streamline drug discovery and development.
Céline Locas, MSc
Advisor, Preclinical Toxicology
Ms. Locas has over 20 years of experience in the pharmaceutical industry. She is currently consultant in preclinical toxicology with a comprehensive experience in drug development in the pharmaceutical industry. Prior to managing her own consultancy company, she held scientific positions of increasing responsibilities within Vertex, Virochem Pharma, Shire BioChem and its predecessor BioChem Pharma.
Over the years, Ms Locas has overseen numerous international preclinical safety programs in a variety of areas including, but not limited to, antiviral (HCV,HIV) and oncology. She was also deeply involved in the due diligence process which resulted in the acquisition of Virochem Pharma by Vertex Pharmaceutical in March 2009. Ms. Locas is a full member of the Society of Toxicology, the American College of Toxicology and Round Table of Toxicology Consultant. Ms. Locas holds a Bachelors degree in Biochemistry and a Masters Degree from the University of Montreal in Pharmaceutical Science with a specialization in Drug Development.
François Ravenelle, PhD
Advisor, Product Development
François Ravenelle joined the Verlyx team in July, 2011 as Senior Director, Product Development. Dr. Ravenelle obtained his PhD in Chemistry in 2002 from McGill University in Montreal and immediately joined ranks of the pharmaceutical and biotechnological industry. From 2002 to 2008, he worked for Labopharm Inc. in various positions including Associate Director, Technology Innovation and Director, Business Development. Before joining Verlyx, he was Director of Pharmaceutical Development at Theratechnologies Inc. where he worked on the development of therapeutic peptides. He is presently Chief Operating Officer and Co-Founder of Inversago Pharma Inc. Over the last fifteen years, Dr. Ravenelle has acquired a wide range of pharmaceutical development experiences ranging from early product development to licensing of technologies.